Talacotuzumab (anti-IL-3Ra)是一种 IgG1 型完全人源化的 CD123 中和单克隆抗体,含有修饰的 Fc 结构。Talacotuzumab (anti-IL-3Ra)对 CD123、CD32b/c、CD16-158F、CD16-158V 的 KD 分别为 0.43 nM、188 nM、46 nM、16.8 nM。Talacotuzumab (anti-IL-3Ra)抑制 IL-3 与 CD123 的结合,从而拮抗靶细胞中的 IL-3 信号传导。Talacotuzumab (anti-IL-3Ra)使 Fc 区发生突变以增加对 CD16 (FcγRIIIa) 的亲和力,从而增强抗体依赖性细胞介导的细胞毒性 (ADCC)。Talacotuzumab (anti-IL-3Ra)在体内非常有效地减少急性髓性白血病 (AML) 异种移植小鼠模型中的白血病细胞生长。
Talacotuzumab (anti-IL-3Ra) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab (anti-IL-3Ra) has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab (anti-IL-3Ra) inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab (anti-IL-3Ra) has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab (anti-IL-3Ra) is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models.